Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer.
Flawless balance sheet with limited growth.
Share Price & News
How has Zymeworks's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZYME's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ZYME exceeded the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: ZYME exceeded the US Market which returned 9.7% over the past year.
Price Volatility Vs. Market
How volatile is Zymeworks's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Zymeworks undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ZYME's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ZYME's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ZYME is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ZYME is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZYME's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZYME is good value based on its PB Ratio (3.2x) compared to the US Biotechs industry average (3.6x).
How is Zymeworks forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZYME is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZYME is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZYME is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZYME's revenue (50% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: ZYME's revenue (50% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZYME is forecast to be unprofitable in 3 years.
How has Zymeworks performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZYME is currently unprofitable.
Growing Profit Margin: ZYME is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZYME is unprofitable, and losses have increased over the past 5 years at a rate of -43% per year.
Accelerating Growth: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: ZYME has a negative Return on Equity (-31.19%), as it is currently unprofitable.
How is Zymeworks's financial position?
Financial Position Analysis
Short Term Liabilities: ZYME's short term assets ($504.6M) exceed its short term liabilities ($72.9M).
Long Term Liabilities: ZYME's short term assets ($504.6M) exceed its long term liabilities ($41.3M).
Debt to Equity History and Analysis
Debt Level: ZYME is debt free.
Reducing Debt: ZYME had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZYME has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ZYME has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 10.5% each year
What is Zymeworks's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZYME's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZYME's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZYME's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ali Tehrani (47yo)
Dr. Ali Tehrani, Ph.D. is a Co-Founder of Zymeworks, Inc. and serves as its Chief Executive Officer and President. Dr. Tehrani has been an integral part of many of Zymeworks' corporate achievements, includ ...
CEO Compensation Analysis
Compensation vs Market: Ali's total compensation ($USD3.28M) is below average for companies of similar size in the US market ($USD4.76M).
Compensation vs Earnings: Ali's compensation has increased whilst the company is unprofitable.
|Co-Founder||no data||US$3.28m||0.70% $11.6m|
|Chief Scientific Officer & Executive VP of Early Development||1.75yrs||US$1.34m||0.064% $1.1m|
|Chief People Officer||0.67yr||US$2.39m||no data|
|Chief Medical Officer||4yrs||US$1.40m||0.012% $195.8k|
|Executive VP of Business Operations & CFO||no data||US$1.05m||0.021% $349.0k|
|Vice President of Technology||no data||US$497.90k||no data|
|VP of Legal & Corporate Secretary||no data||no data||no data|
|Senior Vice President of Discovery Research||4.25yrs||US$400.71k||no data|
|Senior Vice President of Technical & Manufacturing Operations||1.25yrs||no data||no data|
|Senior Vice President of Commercial||no data||no data||no data|
Experienced Management: ZYME's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Co-Founder||no data||US$3.28m||0.70% $11.6m|
|Independent Director||3.33yrs||US$172.16k||no data|
|Independent Chair of the Board of Directors||0.75yr||US$184.19k||no data|
|Independent Director||3.33yrs||US$107.79k||no data|
|Independent Director||0.25yr||no data||no data|
|Independent Director||1yr||US$392.85k||no data|
|Independent Director||2.83yrs||US$160.61k||no data|
|Independent Director||1yr||US$392.48k||0.016% $274.5k|
Experienced Board: ZYME's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ZYME insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.1%.
Zymeworks Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Zymeworks Inc.
- Ticker: ZYME
- Exchange: NYSE
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.667b
- Shares outstanding: 45.54m
- Website: https://www.zymeworks.com
Number of Employees
- Zymeworks Inc.
- 1385 West 8th Avenue
- Suite 540
- British Columbia
- V6H 3V9
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ZYME||NYSE (New York Stock Exchange)||Yes||Common Shares||US||USD||Apr 2017|
|ZYME||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Apr 2017|
|0OX||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 2017|
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and collaboration with Applied BioMath, LLC. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/06 06:12|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.